Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kirsten R Bergmann

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Journal of Pharmacokinetics and Pharmacodynamics|September 15, 2020
Population pharmacokinetics and pharmacodynamics of a novel vascular adhesion protein-1 inhibitor using a multiple-target mediated drug disposition modelNelleke Snelder, Sven Hoefman, Alberto Garcia-Hernandez, et al.
Journal of Pharmacokinetics and Pharmacodynamics|September 15, 2020
Mechanism-based modeling of the effect of a novel inhibitor of vascular adhesion protein-1 on albuminuria and renal function markers in patients with diabetic kidney diseaseSven Hoefman, Nelleke Snelder, Martijn van Noort, et al.
CPT: Pharmacometrics & Systems Pharmacology|August 8, 2023
Item response theory in early phase clinical trials: Utilization of a reference model to analyze the Montgomery-Åsberg Depression Rating ScaleMarije E Otto, Kirsten R Bergmann, Marieke L de Kam, et al.
Therapeutic Drug Monitoring|July 12, 2021
Theoretical Performance of Nonlinear Mixed-Effect Models Incorporating Saliva as an Alternative Sampling Matrix for Therapeutic Drug Monitoring in Pediatrics: A Simulation StudyMatthijs D Kruizinga, Frederik E Stuurman, Gertjan J A Driessen, et al.
FEMS Microbiology Letters|November 19, 2011
Development of antibiotic resistance and up-regulation of the antimutator gene pfpI in mutator Pseudomonas aeruginosa due to inactivation of two DNA oxidative repair genes (mutY, mutM)Lotte Frigaard Mandsberg, Maria D Maciá, Kirsten R Bergmann, et al.
British Journal of Clinical Pharmacology|November 23, 2021
Population pharmacokinetics of clonazepam in saliva and plasma: Steps towards noninvasive pharmacokinetic studies in vulnerable populationsMatthijs D Kruizinga, Rob G J A Zuiker, Kirsten R Bergmann, et al.
Alzheimer'S & Dementia (New York, N. Y.)|October 21, 2020
Safety, pharmacokinetics, and pharmacodynamics of Gln-1062, a prodrug of galantamineCharlotte Bakker, Jasper van der Aart, Ellen P Hart, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 14, 2023
Characterization of the Pharmacokinetic and Pharmacodynamic Profile of Apraglutide, a Glucagon-Like Peptide-2 Analog, in Healthy VolunteersFederico Bolognani, Annelieke C Kruithof, Pascal Schulthess, et al.
Clinical and Translational Science|July 30, 2020
First Clinical Study with AP30663 - a K<sub>Ca</sub> 2 Channel Inhibitor in Development for Conversion of Atrial FibrillationPim Gal, Erica S Klaassen, Kirsten R Bergmann, et al.
Clinical Pharmacology and Therapeutics|January 29, 2022
OX40L Inhibition Suppresses KLH-driven Immune Responses in Healthy Volunteers: A Randomized Controlled Trial Demonstrating Proof-of-Pharmacology for KY1005Mahdi Saghari, Pim Gal, Sally Gilbert, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Journal of Pharmacokinetics and Pharmacodynamics|September 15, 2020
Population pharmacokinetics and pharmacodynamics of a novel vascular adhesion protein-1 inhibitor using a multiple-target mediated drug disposition modelNelleke Snelder, Sven Hoefman, Alberto Garcia-Hernandez, et al.
Journal of Pharmacokinetics and Pharmacodynamics|September 15, 2020
Mechanism-based modeling of the effect of a novel inhibitor of vascular adhesion protein-1 on albuminuria and renal function markers in patients with diabetic kidney diseaseSven Hoefman, Nelleke Snelder, Martijn van Noort, et al.
CPT: Pharmacometrics & Systems Pharmacology|August 8, 2023
Item response theory in early phase clinical trials: Utilization of a reference model to analyze the Montgomery-Åsberg Depression Rating ScaleMarije E Otto, Kirsten R Bergmann, Marieke L de Kam, et al.
Therapeutic Drug Monitoring|July 12, 2021
Theoretical Performance of Nonlinear Mixed-Effect Models Incorporating Saliva as an Alternative Sampling Matrix for Therapeutic Drug Monitoring in Pediatrics: A Simulation StudyMatthijs D Kruizinga, Frederik E Stuurman, Gertjan J A Driessen, et al.
FEMS Microbiology Letters|November 19, 2011
Development of antibiotic resistance and up-regulation of the antimutator gene pfpI in mutator Pseudomonas aeruginosa due to inactivation of two DNA oxidative repair genes (mutY, mutM)Lotte Frigaard Mandsberg, Maria D Maciá, Kirsten R Bergmann, et al.
British Journal of Clinical Pharmacology|November 23, 2021
Population pharmacokinetics of clonazepam in saliva and plasma: Steps towards noninvasive pharmacokinetic studies in vulnerable populationsMatthijs D Kruizinga, Rob G J A Zuiker, Kirsten R Bergmann, et al.
Alzheimer'S & Dementia (New York, N. Y.)|October 21, 2020
Safety, pharmacokinetics, and pharmacodynamics of Gln-1062, a prodrug of galantamineCharlotte Bakker, Jasper van der Aart, Ellen P Hart, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 14, 2023
Characterization of the Pharmacokinetic and Pharmacodynamic Profile of Apraglutide, a Glucagon-Like Peptide-2 Analog, in Healthy VolunteersFederico Bolognani, Annelieke C Kruithof, Pascal Schulthess, et al.
Clinical and Translational Science|July 30, 2020
First Clinical Study with AP30663 - a K<sub>Ca</sub> 2 Channel Inhibitor in Development for Conversion of Atrial FibrillationPim Gal, Erica S Klaassen, Kirsten R Bergmann, et al.
Clinical Pharmacology and Therapeutics|January 29, 2022
OX40L Inhibition Suppresses KLH-driven Immune Responses in Healthy Volunteers: A Randomized Controlled Trial Demonstrating Proof-of-Pharmacology for KY1005Mahdi Saghari, Pim Gal, Sally Gilbert, et al.
Pageof 2